While $VIR's competitor $MIRM has already reported a phase 3 result in hepatitis delta from its monoclonal antibody, I believe VIR's antibody + siRNA will perform even better in hepatitis delta, given prior phase 2 data.
seekingalpha.com/article/495…
1
454
Also encouraging is $INCY's '890 compound, a next-gen immunotherapy with activity in MSS CRC, even in liver metastasis. Compare that to say $AGEN's bot/bal, where activity is predominantly in non-liver metastasis patients. I took a look here.
seekingalpha.com/article/495…
1
485
$VSTM (long). Upcoming catalyst on October 14 is updated data from a trial of VS-7375, an oral KRAS G12D inhibitor. The same drug is under development by GenFleet Therapeutics in China, who are reporting an update from their drug on October 15.
$VSTM is also looking to combine VS-7375 with $ERAS's pan-ras inhibitor, a combination that could rival $RVMD's zoldonrasib plus daraxonrasib combo in the future.
seekingalpha.com/article/495…
1
3
853
There's an underlying commercial story there too with $VSTM, the company markets Avmapki Fakzynja Co-pack (avutometinib with defactinib) for LGSOC patients. That product is only a year into its launch, so doesn't yet offset expenses.
1
416
$DERM is in a nice upward channel since lows in late March. Still holding the name, I expect it to perform over time with Emrosi sales continuing to ramp.
$FATE is already underway on a potentially registrational phase 2 trial of its off-the-shelf cell therapy, FT819, for lupus nephritis.
1
3
740
$FATE also previously reported data from phase 1 work with FT836 in colorectal cancer, showing its off-the-shelf cell therapy could invade that solid tumor and persist.
seekingalpha.com/article/494…
2
433
$SYRE's recent data with SPY072, an anti-TL1A, in rheumatoid arthritis were a bit disappointing. The company has two more shots on goal in Q4'26 with '072 with readouts in psoriatic arthritis and axial spondyloarthritis.
602
Remember Geron? After lackluster sales performance in 2025, $GERN has produced Rytelo sales growth in 2026, with Q2'26's $57.5M in net product revenues a 11% increase from Q1'26. Management has guided however, for growth to be backloaded in 2026, so further growth may be ahead.
1
7
1,397
Beyond that $GERN has a shot on goal in myelofibrosis. There is some movement in myelofibrosis however, $KPTI plans to submit for approval of selinexor.
seekingalpha.com/article/493…
2
858
I do think $ALT's pemvidutide could have something to add to the mix with its differentiated profile, but a phase 3 result is years away. There is phase 2 data in 2027 for alcohol-associated liver disease, however.
seekingalpha.com/article/493…
3
846
$MDGL sold off with Q2'26, although there has been some recovery since, it might be tied to $XBI recovery in general. Either way, $NVO's semaglutide launch in MASH hasn't stopped Rezdiffra growing.
seekingalpha.com/article/493…
1
5
867
The anti-CCR8 field still has some players $GILD $BMS $ABBV despite other players dropping out. $CHRS has four anti-CCR8 readouts in mid-2026/H2'26, plus data from a trial in HCC of its anti-IL-27.
seekingalpha.com/article/492…
1
921
$TARS (I'm long) Q1'26 net product sales of Xdemvy were down from Q4'25. Up to this point in the Xdemvy launch, each quarter had beaten the prior quarter, despite seasonal variation. Nonetheless, script numbers and comments from the CFO suggest a strong Q2'26 rebound.
1
591
$TARS also has H1'27 readouts in ocular rosacea and Lyme disease prevention on tap, with prior results in papulopustular rosacea and tick-killing trials potentially increasing their chances of success.
seekingalpha.com/article/492…
1
540
The iRenix acquisition has been met with a lukewarm reaction for $TARS. A phase 3 trial of ocular antiseptic, IRX-101, will provide a readout further down the track (2028) and the opportunity to bring in revenues beyond lotilaner.
373



